11月12日消息,制药商阿斯利康首席执行官苏博科(Pascal Soriot)称,公司仍然致力于在中国开展业务,既是为了患者,也是为了创新。针对该公司当地管理团队成员正在接受中国执法机构的调查,苏博科表示,对调查的细节知之甚少,该公司在中国有“强有力”的合规政策,已采取新措施来识别任何潜在的违规行为。此前,阿斯利康首席财务官Aradhana Sarin表示,目前中国区相关调查仅针对个人,不涉及公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.